61.25
3.43 (5.93%)
| Previous Close | 57.82 |
| Open | 59.11 |
| Volume | 3,980,053 |
| Avg. Volume (3M) | 1,560,524 |
| Market Cap | 8,291,964,416 |
| Price / Earnings (TTM) | 45.71 |
| Price / Earnings (Forward) | 18.69 |
| Price / Sales | 3.26 |
| Price / Book | 1.95 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Profit Margin | 7.39% |
| Operating Margin (TTM) | 16.40% |
| Diluted EPS (TTM) | 1.34 |
| Quarterly Revenue Growth (YOY) | -1.40% |
| Quarterly Earnings Growth (YOY) | 76.30% |
| Total Debt/Equity (MRQ) | 2.27% |
| Current Ratio (MRQ) | 4.45 |
| Operating Cash Flow (TTM) | 645.55 M |
| Levered Free Cash Flow (TTM) | 639.43 M |
| Return on Assets (TTM) | 5.90% |
| Return on Equity (TTM) | 4.63% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Mixed |
| Medical Devices (Global) | Bearish | Mixed | |
| Stock | Globus Medical, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 3.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 1.13 |
|
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 0.69% |
| % Held by Institutions | 100.94% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sculptor Capital Lp | 31 Mar 2025 | 2,092,838 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (Piper Sandler, 30.61%) | Buy |
| Median | 74.00 (20.82%) | |
| Low | 68.00 (Truist Securities, 11.02%) | Hold |
| Average | 74.00 (20.82%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 57.42 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 12 May 2025 | 68.00 (11.02%) | Hold | 59.01 |
| 11 Apr 2025 | 80.00 (30.61%) | Hold | 72.59 | |
| Piper Sandler | 09 May 2025 | 80.00 (30.61%) | Buy | 55.82 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 15 May 2025 | Announcement | Globus Medical Announces $500 Million Share Repurchase Program |
| 08 May 2025 | Announcement | Globus Medical Reports First Quarter 2025 Results |
| 17 Apr 2025 | Announcement | Globus Medical Schedules First Quarter Earnings Release and Conference Call |
| 03 Apr 2025 | Announcement | Globus Medical completes acquisition of Nevro Corp. |
| 11 Mar 2025 | Announcement | Globus Medical extends versatility of Advanced Materials Science™ anterior interbody portfolio with launch of COHERE™ ALIF Spacer and Modulus™ ALIF Blades |
| 06 Mar 2025 | Announcement | Globus Medical to feature ExcelsiusFlex™ for Total Knee Arthroplasty at the American Academy of Orthopedic Surgeons Annual Meeting |
| 05 Mar 2025 | Announcement | Globus Medical to participate in the Canaccord Genuity 2025 Musculoskeletal Conference |
| 04 Mar 2025 | Announcement | Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |